WO2025133707 - ANTI-TDP-43 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/133707
Publication Date
26.06.2025
International Application No.
PCT/IB2024/000774
International Filing Date
19.12.2024
Title **
[English]
ANTI-TDP-43 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-TDP-43 ET LEURS UTILISATIONS
Applicants **
VECTORY THERAPEUTICS B.V.
Inventors
KONSTANTINOVA, Pavlina
VAN DEVENTER, Sander
POS, Wouter
PASTEUNING-VUHMAN, Svitlana
Priority Data
63/611,860
19.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4077 | |
| EPO | Filing, Examination, Granting | 43042 | |
| Japan | Filing, Examination, Granting | 3600 | |
| South Korea | Filing, Examination, Granting | 4921 | |
| USA | Filing, Examination, Granting | 18790 |
Total:
74,430
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are antibodies and polypeptides that specifically bind to TDP-43. Also provided are pharmaceutical compositions comprising these antibodies, polynucleotides encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.[French]
L'invention concerne des anticorps et des polypeptides qui se lient spécifiquement à TDP-43. L'invention concerne également des compositions pharmaceutiques comprenant ces anticorps, des polynucléotides codant ces anticorps, des vecteurs d'expression et des cellules hôtes pour la fabrication de ces anticorps, et des méthodes de traitement d'un sujet à l'aide de ces anticorps.